- Home
- ALEC vs NKTX Comparison
ALEC vs NKTX Comparison
Compare ALEC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- NKTX
- Stock Information
- Founded
- ALEC 2013
- NKTX 2015
- Country
- ALEC United States
- NKTX United States
- Employees
- ALEC N/A
- NKTX N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- NKTX Health Care
- Exchange
- ALEC Nasdaq
- NKTX Nasdaq
- Market Cap
- ALEC 124.0M
- NKTX 123.5M
- IPO Year
- ALEC 2019
- NKTX 2020
- Fundamental
- Price
- ALEC $1.67
- NKTX $1.81
- Analyst Decision
- ALEC Buy
- NKTX Strong Buy
- Analyst Count
- ALEC 7
- NKTX 6
- Target Price
- ALEC $4.70
- NKTX $14.40
- AVG Volume (30 Days)
- ALEC 544.5K
- NKTX 461.4K
- Earning Date
- ALEC 08-06-2025
- NKTX 08-12-2025
- Dividend Yield
- ALEC N/A
- NKTX N/A
- EPS Growth
- ALEC N/A
- NKTX N/A
- EPS
- ALEC N/A
- NKTX N/A
- Revenue
- ALEC $88,339,000.00
- NKTX N/A
- Revenue This Year
- ALEC N/A
- NKTX N/A
- Revenue Next Year
- ALEC $319.82
- NKTX N/A
- P/E Ratio
- ALEC N/A
- NKTX N/A
- Revenue Growth
- ALEC N/A
- NKTX N/A
- 52 Week Low
- ALEC $0.87
- NKTX $1.31
- 52 Week High
- ALEC $6.78
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- ALEC 58.62
- NKTX 51.92
- Support Level
- ALEC $1.41
- NKTX $1.68
- Resistance Level
- ALEC $1.56
- NKTX $1.80
- Average True Range (ATR)
- ALEC 0.11
- NKTX 0.08
- MACD
- ALEC -0.00
- NKTX 0.00
- Stochastic Oscillator
- ALEC 95.96
- NKTX 79.55
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.